• A new drug, daraxonrasib, significantly extends survival time for advanced pancreatic cancer patients.
• The medication has doubled the median survival time to 13.2 months compared to standard chemotherapy.
• Patients experienced fewer severe side effects and improved quality of life on the experimental drug.
• The FDA plans to expedite the review process for daraxonrasib and has initiated an expanded access program.
• Research indicates that daraxonrasib targets a previously "undruggable" mutation in pancreatic cancer.

In a significant breakthrough for pancreatic cancer treatment, the experimental drug daraxonrasib has been shown to nearly double the survival time for patients with advanced stages of the disease. The findings indicate a median survival of 13.2 months for those taking the drug, compared to just 6.7 months for patients receiving standard chemotherapy, marking a "very large step forward" in treatment options, as stated by Dr. Zev Wainberg of UCLA, who helped lead the study conducted on 500 patients, presented at the American Society for Clinical Oncology meeting, and published in the New England Journal of Medicine, according to NPR, Reuters, and CBS News.

Daraxonrasib works by blocking a mutated protein responsible for tumor growth in over 90% of pancreatic cancer cases, a target that has been difficult to effectively treat. This novel therapy reduced the risk of death by 60% among participants who had previously failed chemotherapy treatments. "It ticks all of the boxes," noted Dr. Rachna Shroff of the University of Arizona Cancer Center, emphasizing the unprecedented improvement for patients whose cancer had progressed after standard chemotherapy, according to NPR and Reuters.

The trial not only highlighted improved survival rates but also noted that many patients reported a better quality of life, with significant reductions in pain and a higher likelihood of resuming everyday activities. This is a stark improvement over chemotherapy, as many patients using daraxonrasib were capable of continuing their treatment longer than those receiving conventional methods. Patients' experiences have varied, but overall, the feedback has shown less severe side effects, such as manageable rashes and mouth sores, giving rise to the possibility of treating a patient population that has historically been underserved, as reported by Reuters and CBS News.

The FDA has initiated a program allowing expanded access to daraxonrasib, catering specifically to pancreatic cancer patients who meet certain criteria. The agency is also expediting the review process for this innovative treatment. Former U.S. Senator Ben Sasse, who has spoken publicly about his positive experiences while using the drug, remarked on his relief from pain and significant reduction in tumor size, calling it a "miracle drug," which has led to an influx of inquiries from oncologists about this experimental treatment, according to NPR and Reuters.

This drug represents a new class of cancer treatments called RAS(ON) inhibitors, specifically targeting mutations within the RAS gene family that are critical to pancreatic cancer's progression. Research on daraxonrasib's effectiveness on different subtypes of KRAS mutations continues, with the potential for further enhancements in treatment protocols, according to CBS News and Reuters.